Overview
Mechanistic Evaluation of Response in TRD (MERIT)
Status:
Completed
Completed
Trial end date:
2021-07-30
2021-07-30
Target enrollment:
0
0
Participant gender:
All
All
Summary
To evaluate the relapse prevention of AXS-05 relative to placebo in subjects with treatment resistant depression (TRD). This is a randomized, double-blind, placebo-controlled study to evaluate AXS-05 compared to placebo in delaying relapse of depressive symptoms in patients with TRD who are in stable remission after treatment with AXS-05.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Axsome Therapeutics, Inc.
Criteria
Key Eligibility Criteria:- Ongoing symptoms of depression despite receiving treatment with two or more prior
antidepressants during the current major depressive episode, prior to receiving AXS-05
- Agree to use adequate method of contraception for the duration of the study
- Additional criteria may apply